Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination with Binimetinib in Patients with Gastrointestinal Stromal Tumor (GIST)

Next Previous
X
Search
Trial Profile

A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination with Binimetinib in Patients with Gastrointestinal Stromal Tumor (GIST)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Ripretinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MEKi Combo trial
  • Sponsors Deciphera Pharmaceuticals

    • Most Recent Events

    • 24 Sep 2023 This trial has been discontinued in Spain.
    • 15 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: The Sponsor decided to discontinue this study due to a corporate restructuring intended to prioritize clinical development of select programs. No patients enrolled in this study and no patients received investigational product.
    • 03 Aug 2021 According to a Deciphera Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top